Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Phase 2 Not yet recruiting 50 enrolled Shanghai Henlius Biotech

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.

Timeline

Start: 2022-07-15
Primary completion: 2025-10-15
Completion: 2026-10-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OXA	Unknown	85 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	400 mg/m2	Intravenous
Subject	PIMURUTAMAB	Monoclonal antibody	1000 mg	Intravenous
Subject	Serplulimab	Monoclonal antibody	200 mg	Intravenous
Subject	fluorouracil	Small molecule	400 mg/m2	Intravenous

Indications

No indication recorded.